Alemtuzumab dosing

Pharmacokinetics The pharmacokinetic profile of alemtuzumab was studied in a rising-dose trial in non-Hodgkin s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Campath was administered once weekly for a maximum of 12 weeks. Following intravenous infusions over a range of doses, the maximum serum concentration (C ax) and the area under the curve (AUC) showed relative dose pro-... 

Similar to the result of FCGR polymorphism with rituximab therapy for CLL, Lin et al. (70) reported that the FCGR3A and FCGR2A polymorphism did not show any difference in response rate of relapsed CLL patients when treated with alemtuzumab (stepped-up dose schedule from 3 mg to 30 mg during the first week and then given at 30 mg three times a week for 12 weeks). 

Campath Alemtuzumab Humanized IgGi CD52 B-cell CLL IV 3-30 mg 3 doses per week... 

Of 22 patients, median age 61 years, who had received a median of three previous types of therapy for mycosis fungoides or Sezary syndrome and were given alemtuzumab in increasing doses (from 3 to 30 mg three times a week for 12 weeks), 11 had no infectious complications, one had fatal pulmonary aspergillosis 2.5 months after the end of treatment, and another contracted fatal Mycobacterium pneumonia 10 months after the end of treatment (7). 

I. F. Khouri, M. Albitar, R. M. Saliba, C. Ippoliti, Y. C. Ma, M. J. Keating, and R. E. Camplin, Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant 33 833-837 (2004). 

New immunosuppressive protocols are being used to promote tolerance in transplant recipients to avoid long-term use of immunosuppressants. These protocols typically use high doses of RATG or alemtuzumab before transplantation and low-dose immunosuppression after transplantation with gradual weaning. 

Alemtuzumab (Campath) CD52 2001 CV, pulmonary in monkeys iBP, HR No information 1-month monkey (MAHA response precluded further dosing) Lymphocytopenia Cytopenias, Infections... 

Patients should be premedicated with an oral or intravenous ucocorticoid, an antihistamine, and an analgesic 30-60 minutes before each infusion of alemtuzumab during dose escalation. 

Karlsson C, Lundin J, Kimby E, Keimedy B, Moreton P, Hillmen P, Osterborg A. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 2009 144 78-85. 

---